Rigid phencyclidine analogues. Binding to the phencyclidine and σ1 receptors

Journal of Medicinal Chemistry

Volumn 41, Issue 4, 1998, Pages 468-477

  Moriarty, Robert M ^a   Enache, Livia A ^a   Zhao, Lei ^a   Gilardi, Richard ^b   Mattson, Mariena V ^c   Prakash, Om ^a,d  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b NAVAL RESEARCH LABORATORY   (United States)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^d KURUKSHETRA UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

1 PIPERIDINO 7,8 BENZOBICYCLO[4.2.0]OCTENE; 1 PIPERIDINOBENZOBICYCLO[2.2.1]HEPTENE; 1 PIPERIDINOBENZOBICYCLO[2.2.2]OCTENE; DIZOCILPINE; PHENCYCLIDINE; PHENCYCLIDINE DERIVATIVE; PHENCYCLIDINE RECEPTOR; SIGMA 1 OPIATE RECEPTOR; SIGMA RECEPTOR LIGAND; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BRAIN HOMOGENATE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; NONHUMAN; RAT;

ANIMALS; BRAIN; CRYSTALLOGRAPHY, X-RAY; INDICATORS AND REAGENTS; LIGANDS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; PHENCYCLIDINE; RADIOLIGAND ASSAY; RATS; RECEPTORS, PHENCYCLIDINE; RECEPTORS, SIGMA; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0032510058     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm970059p     Document Type: Article

References (96)

1. Greifenstein, F. E.; Yoshitake, J.; De Vault, M.; Gajewski, J. E. A study of 1-aryIcyclohexylamine for anesthesia. Anesth. Analg. 1958, 37, 283-284.
2. Chen, G.; Ensor, C. R.; Russell, D.; Bohner, B, The pharmacology of 1-(1-phenylcyclohexy)piperidine·HCl. J. Pharmacol. Exp. Ther. 1959, 127, 241-250.
3. Chen, G.; Weston, J. K. The analgesic and anesthetic effects of 1-(1-phenylcyclohexyl)piperidine·HCl on the monkey. Anesth. Analg. 1960, 39, 132-137.
4. Luby, E. D.; Cohen, B. D.; Rosenbaum, G.; Gottlieb, J. S.; Kelley, R. Study of a new schizophrenimimetic drug-Sernyl. Arch. Neurol. Psychiatry 1959, 81, 363-369.
5. Luby, E. D.; Gottlieb, J. S.; Cohen, B. D.; Rosenbaum, G.; Domino, E. F. Model psychoses and schizophrenia. Am. J. Psychiatry 1962, 119, 61-67.
6. Rainey, J. M.; Crowder, M. K. Prolonged psychosis attributed to phencyclidine: report of three cases. Am. J. Psychiatry 1975, 132, 1076-1078.
7. Fauman, B.; Baker, F.; Coppleson, L. W.; Rosen, P.; Segal, M. B. Psychosis induced by phencyclidine. J. Am. Coll. Emerg. Physicians 1975, 4, 223-225.
8. Luisada, P.; Brown, B. I. Clinical management of phencyclidine psychosis. Clin. Toxicol. 1978, 9, 539-545.
9. Balster, R. L.; Chait, L. D. The behavioral pharmacology of phencyclidine. Clin. Toxicol. 1976, 9, 513-528.
10. (a) Johnson, K. M.; Jones, S. M. Neuropharmacology of phencyclidine: Basic mechanisms and therapeutic potential. Annu. Rev. Pharmacol. Toxicol. 1990, 39, 707-750.
11. (b) Johnson, K. M. Neurochemistry and neurophysiology of phencyclidine. In Psychopharmacology: Third Generation of Progress; Meltzer, H. Y., Ed.; Raven; New York: 1987; pp 1581-1588.
12. Contreras, P. C.; Monohan, J. B.; Lanthorn, T. H.; Pullan, L. M.; Di Maggio, D, A.; et al. Phencyclidine: physiological actions, interactions with excitatory amino acids and endogenous ligands. Mol. Neurobiol. 1987, 1, 191-211.
13. Chen, G.; Bohner, B. Anticonvulsant properties of 1-(1- phenylcyclohexyl)piperidine·HCl and certain other drugs. Proc. Soc. Exp. Biol. Med. 1961, 106, 632-635.
14. Leander, J. D.; Rathbun, R. C.; Zimmeman, D. M. Anticonvulsant effects of phencyclidine-like drugs: relation to N-methyl-D- aspartic acid antagonism. Brain Res. 1988, 454, 368-372.
15. Sagratella, S.; Niglio, T.; Scotti de Carolis, A, An investigation on the mechanism of anticonvulsant action of ketamine and Phencyclidine on convulsions due to cortical application of penicillin in rabbits. Pharmacol. Res. Commun. 1989, 17, 773-786.
16. Hayes, B. A.; Balster, R. L. Anticonvulsant properties of phencyclidine-like drugs in mice. Eur. J. Pharmacol. 1985, 117, 121-125.
17. (a) Contreras, P. C.; Rice, K. C.; Jacobson, A. E.; O'Donohue, T. L. Stereotyped behavior correlates better than ataxia with phencyclidine-receptor interactions. Eur. J. Pharmacol. 1986, 121, 9-18.
18. (b) Jacobson, A. E.; Harrison, E. A., Jr.; Mattson, M. V.; Rafferty, M. F.; Rice, K. C.; Woods, J. H.; Winger, G.; Solomon, R. E.; Lessor, R. A.; Silverton, J. V. Enantiomeric and diastereomeric dioxadrols: Behavioral, biochemical and chemical determination of configuration necessary for phencyclidine-like properties. J. Pharmacol. Exp. Ther. 1987, 243, 110-117.
19. Vincent, J. P.; Kartalowski, B.; Geneste, P.; Kamenka, J. M.; Lazdunski, M. Interaction of Phencyclidine ("Angel Dust") with a Specific Receptor in Rat Brain Membranes. Proc. Natl. Acad. Sci. U.SA, 1979, 76, 4678-4682.
20. 3H]-Phencyclidine Binding in Rat Central Nervous System. Proc. Natl. Acad. Sci. U.S.A. 1979, 76, 5372-5376.
21. (e) Geneste, P.; Herrmenn, P.; Kamenka, J. M.; Pons, A. Bull. Soc. Chim. Fr. 1975, 1619-1626 (in French),
22. (f) Gabrielevitz, A.; Kloog, Y.; Kalir, A.; Balderman, D.; Sokolovsky, M. Interaction of phencyclidine and its new adamantyl derivatives with muscarinic receptors. Life Sci. 1980, 26, 89-95.
23. (g) Thurkauf, A.; Hillary, P.; Mattson, M. V.; Jacobson, A. E.; Rice, K. C. The synthesis, pharmacological action, and receptor binding affinity of the enantiomeric 1-(1-phenyl-3-methylcyclohexyl)piperidines. J. Med. Chem. 1988, 31, 1625-1628.
24. (h) Iorio, M. A.; Tomassini, L.; Mattson, M. V.; George, C.; Jacobson, A. E. Synthesis, stereochemistry and biological activity of the 1-(1-phenyl-2methylcyclohexyljpiperidines and the 1-(1-phenyl-4-methylcyclohexyDpiperidines. Absolute configuration of the potent trans(-)-1-(1-phenyl-2-methylcyclohexyl)piperidine. J. Med. Chem. 1991, 34, 2615-2623.
25. 3H]- SKF 10047 binding sites in rat brain membranes: evidence of multiplicity. Eur. J. Pharmacol. 1987, 136, 231-234.
26. (j) de Costa, B. R.; Mattson, M. V.; George, C.; Linders, J. T. M. Synthesis, configuration, and activity of isomeric 2-phenyl-2-tfv"-piperidinyDbicyclo[3.1.0]hexanes at phencyclidine and a binding sites. J. Med. Chem. 1992, 35, 4704-4712.
27. 3H]TCP: A new tool with high affinity for the PCP receptor in rat brain. Brain Res. 1983, 280, 194-197.
28. Keats, A. S.; Telford, J. Narcotic antagonists as analgesics. In Molecular Modification in Drug Design; Gould, R. F., Ed.; Advances in Chemistry Series 45; American Chemical Society: Washington, DC, 1964; pp 170-176.
29. Wong, E. H. F.; Kemp, J. A.; Priestly, T.; Knight, A. R.; Woodruff, G. N.; Iverson, L. L. The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist. Proc. Natl. Acad. Sci. U.S.A. 1986, 83, 7104-7108.
30. Kemp, J. A.; Priestley, T.; Woodruff, G. N. MK-801, a novel, orally active anticonvulsant, is a potent, non-competitive N-methyl-D-aspartate receptor antagonist. Br. J. Pharmacol. (Proc. Suppl.) 1986, 89, 535P-537P.
31. Woodruff, G. N.; Foster, A. C.; Gill, R.; Kemp, J. A.; Wong, E. H. F.; Ivereen, L. L. The interaction between MK-801 and receptors for N-methyl-D-aspartate: functional consequence. Neuropharmacology 1987, 26, 903-909.
32. Rothman, S. Synaptic release of excitatory amino acid neuretransmitter mediates anoxic neuronal death. J. Neuroaci. 1984, 4, 1884-1891.
33. Simon, R. P.; Swan, J. H.; Griffith, T.; Meldrum, B. S. Blockade of N-methyl-D-aspartate receptors may protect against ischemie damage in the brain. Science 1984, 226, 850-852.
34. Wieloch, T. Hypoglycemia-induced neuronal damage prevented by an N-methyl-D-aspartate antagonist. Science 1985, 230, 681-683.
35. Choi, D. W.; Koh, J.-Y.; Peters, S. Pharmacology of glutamate neurotoxicity in cortical cell culture: attenuation by NMDA antagonists. J. Neurosci. 1988, 8, 185-196.
36. Rondouin, G.; Drian, M.-J.; Chicheportiche, R.; Kamenka, J.-M.; Privat, A. Non-competitive antagonists of N-methyl-D-aspartate receptors protect cortical and hippocampal cell cultures against glutamate neurotoxicity. Neurosci. Lett. 1988, 91, 199-203.
37. Olney, J. W.; Price, M. T.; Fuller, T. A.; Labruyere, J.; Samson, L.; et al. The anti-excitotoxic effects of certain anesthetics, analgesics and sedative-hypnotics. Neuroaci. Lett. 1986, 68, 29-34.
38. Olney, J.; Price, M.; Salles, K. S.; Labruyere, J.; Frierdich, G. MK-801 powerfully protects against N-methyl-D-aspartate neurotoxicity. Eur. J. Pharmocol. 1987, 141, 357-361.
39. Sauer, D.; Nuglish, J.; Rossberg, C.; Mennel, H.-D.; Beck, T.; et al. Phencyclidine reduces postischemic neuronal necrosis in rat hippocampus without changing blood flow. Neurosci. Lett. 1988, 97, 327-332.
40. Watkins, J. C.; Evans, R. H. Excitatory amino acid transmitters. Annu. Rev. Pharmacol. Toxicol. 1981, 27, 165-204
41. Monaghan, D. T.; Bridges, R. J.; Cotman, C. W. The excitatory amino acid receptors: Their classes, pharmacology, and distinct properties in the function of the central nervous system. Annu. Rev. Pharmacol. Toxicol. 1989, 29, 365-402.
42. Carter, A. J. Glycine antagonists: Regulation of the NMDA receptor-channel complex by the strychnine-insensitive glycine site. Drugs Future 1992, 17, 595-613.
43. Kemp, J. A.; Leeson, P. D. The glycine site of the NMDA receptor-five years on. Trends Pharmacol Sci. 1993, 14, 20-25.
44. Cotman, C. W.; Monaghan, D. T.; Ganong, A. H. Excitatory amino acid neurotransmission: NMDA receptors and Hebb-type synaptic plasticity. Annu. Rev. Neurosci. 1988, 11, 61-80.
45. Sugihara, H.; Moriyoshi, K.; Ishii, T.; Masu, M.; Nakanishi, S. Structures and properties of seven isoforms of the NMDA receptor generated by alternative splicing. Biochem. Biophys. Res. Commun. 1992, 185, 826-832.
46. Leeson, P. D.; Iversen, L. L. The glycine site on the NMDA receptor: Structure-activity relationships and therapeutic potential. J. Med. Chem. 1994, 37, 4053-4067.
47. 2+ of NMDA responses in spinal cord neurones. Nature 1984, 309, 261-263.
48. Nowak, L.; Bregestovski, P.; Ascher, P.; Herbet, A.; Prochiantz, A. Magnesium gates L-glutamate activated channels in mouse central neurones. Nature 1984, 307, 462-465.
49. Foster, A. C.; Wong, E. H. F. The novel anticonvulsant MK-801 binds to the activated state of the N-Methyl-D-asparate receptor in rat brain. Br. J. Pharmacol, 1987, 91, 403-409.
50. Huettner, J. E.; Bean, B. P. Block of N-methyl-D-aspartate-activated current by the anticonvulsant MK-801: selective binding to open channels. Proc. Natl, Acad. Sci. U.S.A. 1988, 85, 1307-1311.
51. Fagg, G. E. Phencycline and related drugs bind to the activated N-methyl-D-aspartate receptor channel complex in rat brain membranes. Neurosci. Lett. 1987, 76, 221-227.
52. Johnson, K. M.; Snell, L. D.; Sacaan, A. I.; Jones, S. M. Pharmacological regulation of the phencylidine binding site associated with the NMDA receptor-operated ion channel. Drug. Dev. Res. 1989, 17, 281-297.
53. (a) Thompson, W. J.; Anderson, P. S.; Britcher, S. F.; Lyle, T. A.; Thies, J. E.; Magill, C. A.; Varga, S. L.; Schwering, J. E.; Lyle, P. A.; Christy, M. E.; Evans, B. E.; Colton, C. D.; Holloway, M. K; Springer, J. P.; Hershfield, J. M.; Ball, R. H.; Amato, J. S.; Larson, R. D.; Wong, E. H. F.; Kemp, J. A.; Tricklebank, M. D.; Singh, L.; Oles, R.; Priestly, T.; Marshall, G. R.; Knight, A. R.; Middlemiss, D. N.; Woodruff, G. N.; Iversen, L. L. Synthesis and pharmacological evaluation of a series of dibenzo[a,d]cycloalkenimines as N-methyl-D-aspartate antagonists. J. Med. Chem. 1990, 33, 789-808.
54. (b) Gill, R.; Brazell, C.; Woodruff, G. N.; Kemp, J. A. The neuroprotective action of dizocilpine (MK- 801) in the rat middle cerebral artery occlusion model of focal ischemia. Br. J. Pharmacol. 1991, 103, 2030-2036.
55. Hatfield, R. H.; Gill, R.; Brazell, C. The dose-response relationship and therapeutic window for dizocilpine (MK-801) in rat focal ischemia model. Eur. J. Pharmacol. 1992, 216, 1-7.
56. 3H-catecholamines by rat striatal and hypothalamic synaptosomes. Life Sci. 1976, 18, 1105-1110.
57. 3H]serotonin uptake in synaptosomal preparations from rat brain. Biochem. Pharmacol. 1977, 26, 1435-1439.
58. Martin, W. R.; Eades, C. G.; Thompson, J. A.; Huppier, R. E.; Gilbert, P. E. The effects of morphine and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J. Pharmacol. Exp. Ther. 1976, 217, 517-532.
59. Quirion, R.; Chicheportiche, R.; Contreras, P.; Johnson, K. M.; Lodge, D.; et al. Classification and nomenclature of phencyclidine and sigma receptor sites. Trends Neurosci. 1987, 10, 444-446.
60. 3H-cyclazocine binding to multiple opiate receptor types. Mol. Pharmacol. 1981, 20, 246-254.
61. 3H-ethylketocyclazocine, μ, κ, σ and phencyclidine binding sites in guinea pig brain membranes. Eur. J. Pharmacol. 1985, 109, 33-41.
62. 3H-SKF 10,047 to etrophine-inaccessible sites in guinea pig brain. J. Pharmacol. Exp. Ther. 1982, 223, 284-290.
63. Maurice, T.; Lockhart, B. P. Neuroprotective and anti-amnesic potentials of sigma (σ) receptor ligands. Prog. Neuro-Psychopharmacol. Biol. Psychiat. 1997, 27, 69-102.
64. Su, T. P.; London, E. D.; Jaffe, J. H. Steroid Binding at a Receptors Suggests a Link Between Endocrine, Nervous, and Immune Systems. Science 1988, 240, 219-221.
65. 3H-Alaproclate to Liver Membranes Pharmacol. Toxicol, 1987, 61, 282-287.
66. 3H-Alaproclate to Membranes from Rat Cerebral Cortex. Pharmacol. Toxicol. 1987, 61, 288-292.
67. Ferns, R. M.; Tang, F. L. M.; Chang, K.-J.; Russell, A. Evidence that the Potential Antipsychotic Agent Rimcazole (BW 234U) Is a Specific, Competitive Antagonist of Sigma Sites in Brain. Life Sci. 1986, 38, 2329-2337.
68. Taylor, D. P.; Dekleva, J. A Potential Antipsychotic Agent that Selectively Binds to Sigma Receptors. In: Sigma and Phencyclidine-Like Compounds as Molecular Probes in Biology; NPP Books: Ann Arbor, 1988; pp 345-355.
69. Lehmann, J. Sigma Receptor, Schizophrenia and Cytochrome P-450. Drug News Perspect. 1991, 4, 208-210.
70. Contreras, P. C.; Gray, N. M.; Ragan, D. M.; Lanthorn, T. H. B MY-14802 protects against ischemia-induced neuronal damage in the gerbil. Life Sci. 1992, 51, 1145-1149.
71. Carter, C. J.; Lloyd, K. G.; Zivkovic, B.; Scatton, B. Ifenprodil and SL 82.0715 as cerebral antiischemic agents. III. Evidence for antagonistinc effects at the polyamine modulatory site within the N-methyl-D-aspartate receptor complex. J. Pharmacol. Exp. Ther. 1989, 253, 475-482.
72. Prince, D. A.; Feeser, H. R. Dextromethorphan protects against cerebral infarction in rat model of hypoxia-ischemia. Neurosci. Lett. 1988, 85, 291-296.
73. (a) Long, J. B.; Tidwell, R. E.; Tortella, F. C.; Rice, K. C.; de Costa, B. R. Selective sigma ligands protect against dynorphin A-induced spinal cord injury in rats. Soc. Neurosci. Abs. 1990, 16, 1122, abs 461.4.
74. (b) Contreras, P. C.; Ragan, D. M.; Bremer, M. E.; Lanthorn, T. H.; Gray, N. M.; lyengar, S.; Jacobson, A. E.; Rice, K. C.; de Costa, B. R. Evaluation of 450,488 H analogs for neuroprotective activity in the gerbil. Brain Res. 1991, 546, 79-82.
75. Rao, T. S.; Cler, J.A.; Mick, S. J.; Ragan, D. M.; Lanthorn, T. H.; Contreras, P. C.; lyengar, S.; Wood, P. L. Opipramol, a potent sigma ligand, is an anti-ischemie agent: Neurochemical evidence for an interaction with N-methyl-D-aspartate receptor complex in vivo by cerebral cGMP measurements. Neuropharmacology 1990, 29, 1199-1204.
76. Quirion, R.; Bowen, W. D.; Itzhak, Y.; Junien, J. L.; Musacchio, J. M.; Rothman, R. B.; Su, T. P.; Tarn, S. W.; Taylor, D. P. A proposal for the classification of sigma binding sites. Trends Pharmacol. Sci. 1992, 13, 85-86.
77. Carroll, F. I.; Abraham, P.; Parham, K.; Bai, X.; Zhang, X.; Brine, G. A.; Mascarella, S. W.; Martin, B. R.; May, E. L.; Sauss, C.; DiPaolo, L.; Wallace, P.; Walker, J. M.; Bowen, W. D. Enantiomeric N- substituted N-normetazocines: A comparative study of affinities at σ, PCP, and μ opioid receptors. J. Med. Chem. 1992, 35, 2812-2818.
78. 1 muscarinic antagonists interact with σ recognition sites. Life Set. 1991, 49, 1229-1235.
79. Eaton, T. A.; Houk, K. N.; Watkins, S. F.; Fronczek, F. R. Geometries and conformational Processes in Phencyclidine and a rigid adamantyl analogue: Variable-temperature NMR, X-ray crystallographic, and molecular mechanics studies. J. Med. Chem. 1983, 26, 479-486.
80. (a) Kozikowski, A. P.; Pang, Y. P. Structural determinants of affinity for the phencyclidine binding site of the N-methyl-Daspartate receptor complex: discovery of a rigid phencyclidine analogue of high binding affinity. Mol. Pharmacol. 1990, 37, 350-357.
81. (b) Also see: Casalotti, S. 0.; Kozikowski, A. P.; Fauq, A.; Tuckmantel, W.; Krueger, K. E. Design of an irreversible affinity ligand for the phencyclidine recognition site on the N-methyl-D-aapartate type glutamate receptors. J. Pharmacol. Exp. Ther. 1992, 260, 21-28.
82. Chen, C.; Kozikowski, A. P.; Wood, P. L.; Reynolds, I. J.; Ball, R. G.; Pang, Y. P. Synthesis and biological activity of 8a-Phenyldecahydroquinolines as probes of PCP's binding conformation. A new PCP-like compound with increased in vivo potency. J. Med. Chem. 1992, 35, 1634-1638.
83. Hudkins, R. L.; Mailman, R. B.; DeHaven-Hudkins, D. L. Novel (4-phenylpiperidinyl)- and (4-PhenylpiperazinylJalkyl-spaced esters of l-phenylcyclopentanecarboxylic acids as potent a-selective compounds. J. Med. Chem. 1994, 37, 1964-1970.
84. Su, T. P.; Wu, X.; Cone, E. J.; Kanhiya, S.; Tamara, M. G.; Dodge, A. L.; Parish, D. W. Sigma compounds derived from phencyclidine: Identification of PRE-084, a new, selective sigma ligand. J. Pharmacol. Exp. Ther. 1991, 259, 543-550.
85. Russel, M. G. N.; Baker, R.; Billington, D. C.; Knight, A. K.; Middlemiss, D. N.; Noble, A. J. Benz[f]isoquinoline Analogues as High-Affinity σ Ligands. J. Med. Chem. 1992, 35, 2025-2033.
86. Chambers, M. S.; Baker, R.; Billington, D. C.; Knight, A. K.; Middlemiss, D. N.; Wong, E. H. F. Spiropiperidines as HighAffinity, Selective σ Ligands. J. Med. Chem. 1992, 35, 2033-2039.
87. de Costa, B. R.; Radesca, L.; Di Paolo, L.; Bowen, W. D. Synthesis, characterization, and biological evaluation of a novel class of N-(arylethyl)-N-alkyl-2-(1-pyrrolidinyl) ethylamines: Structural requirements and binding affinity at the σ receptor. J. Med. Chem. 1992, 35, 38-47.
88. Grob, C. A.; Ohta, M.; Renk, E.; Weiss, A. Synthese und Reaktionen 1-substituierter Bicyclo[2.2.2)octane. Helv. Chim. Acta 1958, 41, 1191-1197.
89. Moriarty, R. M.; Khosrowshahi, J. S.; Awashti, A. K; Penmasta, R. A convenient synthesis of 1-aminopolycycloalkanes and their tosylate salts. Synth. Commun. 1988, 18, 1179-1186.
90. Gabrielevitz, A.; Kloog, Y.; Kallic, A.; Balderman, D.; Sokolowsky, M. Interaction of phencyclidine and its new adamantyl derivatives with muscarinic receptors. Life Sci, 1980, 26, 89-95.
91. Eaton, P. E.; Carlson, G. R.; Lee, J. T. Phosphorus pentoxide methanesulfonic acid. A convenient alternative to polyphosphoric acid. J. Org. Chem. 1973, 38, 4071-4073.
92. Moriarty, R. M.; Tuladhar, S. M.; Penmasta, R.; Awashti, A. K. Unpublished results (UIC).
93. Grunewald, G. L.; Ye, Q. Synthesis of benzobicyclo[3.2.1]octanes involving inversion of configuration via an N to O acetyl migration. J. Org, Chem. 1988, 53, 4021-4026.
94. Hunig, S.; Kahanek, H. Diensynthesen mit 1-Diaethylaminobutadien und thermische Spaltung der Addukte. Chem. Ber. 1957, 90, 238-245.
95. Gray, N. M.; Cheng, B. K.; Mick, S. J.; Lair, C. M.; Contreras, P. C. Phencyclidine-like effects of tetrahydroisoquinolines and related compounds. J. Med. Chem. 1989, 32, 1242-1248.
96. 50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.